Aciflox Tablet 200 mg

Aciflox Tablet is a fluoroquinolone antibiotic containing Sparfloxacin (200 mg) as its active ingredient. Manufactured by ACI Limited, this tablet treats bacterial infections like pneumonia, bronchitis, and urinary tract infections. Priced at ৳12.00 per unit, it offers cost-effective therapy with a 10-tablet strip costing ৳120.00.

This medication inhibits bacterial DNA gyrase and topoisomerase IV, disrupting replication. It’s highly effective against gram-positive bacteria, Mycoplasma, and Chlamydia. Clinical trials confirm its efficacy in respiratory, urinary, and sexually transmitted infections. Avoid concurrent use with antacids, as they reduce absorption by 50%.

Dosage: Adults with normal renal function take 400 mg (2 tablets) on Day 1, followed by 200 mg daily for 10 days. For renal impairment (creatinine clearance <50 mL/min), take 200 mg every 48 hours after the initial dose. Swallow tablets whole, with or without food, but avoid magnesium/aluminum-containing antacids.

Side Effects: Common reactions include photosensitivity, diarrhea, nausea, and dizziness. Rarely, QTc prolongation may occur. Store below 30°C, away from light and moisture. Pregnant or breastfeeding women should consult doctors before use. Explore alternatives like Sparfloxacin brands for similar therapeutic benefits.

The recommended daily dose of Sparfloxacin‚ in patients with normal renal function is two 200 mg tablets taken on the first day as a loading dose. Thereafter, one 200 mg tablet should be taken every 24 hours for a total of 10 days of therapy (11 tablets). The recommended daily dose of Sparfloxacin‚ in patients with renal impairment (creatinine clearance <50 mL/min) is two 200 mg tablets taken on the first day as a loading dose. Thereafter, one 200-mg tablet should be taken every 48 hours for a total of 9 days of therapy (6 tablets).

Most of the side effects are mild to moderate in severity and transient in nature. The most frequently reported events with the recommended dosage were: Photosensitivity reaction, Diarrhea, Nausea, Headache, Dyspepsia, Dizziness, Insomnia, Abdominal pain, Pruritus, Taste perversion, QTc interval prolongation, Vomiting, Flatulence, Vasodilatation.

There are no adequate and well controlled studies in pregnant women. Sparfloxacin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Special warnings: Moderate to severe phototoxic reactions have occurred in patients exposed to direct or indirect sunlight or to artificial ultraviolet light (e.g., sunlamps) during or following treatment. Patients should be advised to discontinue Aciflox therapy at the first signs or symptoms of a phototoxicity reaction such as:

• Sensation of skin burning
• Swelling
• Rash
• Itching
• Dermatitis
• Increases in the QTc interval.

The safety and effectiveness of Aciflox in children, adolescents (under the age of 18 years), pregnant women, and lactating women have not been established.

Precaution–

• Adequate hydration of patients receiving Aciflox should be maintained to prevent the formation of a highly concentrated urine.
• Administer Aciflox with caution in the presence of renal insufficiency.
• Avoid the concomitant prescription of medications known to prolong the QTc interval, e.g., erythromycin, terfenadine etc.
• Excessive exposure to sunlight should be avoided.

Geriatric: The pharmacokinetics of Aciflox‚ are not altered in the elderly with normal renal function.

Paediatric: The pharmacokinetics of Aciflox in paediatric subjects have not been studied.

Gender: There are no gender differences in the pharmacokinetics of Aciflox.

Renal insufficiency: In patients with renal impairment (creatinine clearance <50 mL/min), the terminal elimination half-life of Aciflox is lengthened. Single or multiple doses of Aciflox in patients with varying degrees of renal impairment typically produce plasma concentrations that are twice those observed in subjects with normal renal function.

Hepatic impairment: The pharmacokinetics of Aciflox are not altered in patients with mild or moderate hepatic impairment without cholestasis.